Apple Secures Partial Victory in Masimo Patent Dispute Over Redesigned Apple Watch Blood Oxygen Feature, But Original Ban Stands

Apple has received a mixed bag of legal outcomes in its protracted patent infringement dispute with health technology company Masimo concerning the blood oxygen monitoring capabilities of the Apple Watch. Two significant developments emerged this week, offering both a glimmer of relief and a confirmation of previous legal setbacks for the Cupertino giant. An Administrative Law Judge (ALJ) at the International Trade Commission (ITC) delivered an initial determination that Apple’s redesigned blood oxygen feature does not infringe upon Masimo’s patents, while concurrently, the United States Court of Appeals for the Federal Circuit affirmed the ITC’s original exclusion order, permanently banning the sale of Apple Watch models utilizing the original, infringing blood oxygen technology in the U.S.

The Genesis of the Dispute: Masimo vs. Apple

The legal saga between Masimo and Apple traces back several years, rooted in allegations of intellectual property theft and patent infringement. Masimo, a California-based company founded in 1989, is a global leader in non-invasive patient monitoring technologies, particularly known for its advanced pulse oximetry. Their SET® (Signal Extraction Technology) pulse oximetry is widely regarded as a gold standard in medical-grade devices, capable of accurately measuring blood oxygen saturation (SpO2) even in challenging conditions like patient motion and low perfusion.

Masimo’s initial lawsuit against Apple in January 2020 accused the tech giant of poaching key employees and stealing trade secrets related to pulse oximetry technology, subsequently integrating this technology into the Apple Watch Series 6, which debuted with a blood oxygen sensor in September 2020. Masimo CEO Joe Kiani publicly accused Apple of a deliberate strategy to leverage Masimo’s innovations, claiming that Apple had engaged in discussions under the guise of collaboration only to later poach personnel and incorporate their patented technology. Apple vehemently denied these allegations, asserting that its technology was independently developed.

The stakes were high, as the blood oxygen monitoring feature quickly became a cornerstone of Apple Watch’s health capabilities. Especially during the COVID-19 pandemic, the ability for consumers to monitor their SpO2 levels at home gained significant attention, cementing the feature’s perceived value and importance in the wearable health tech market. For Apple, integrating such advanced health functionalities was crucial for its strategy to position the Apple Watch as a comprehensive health and wellness device, moving beyond mere fitness tracking.

A Detailed Chronology of Legal Maneuvers

The legal battle has unfolded across multiple venues, including federal courts and the ITC, each playing a distinct role in intellectual property disputes.

• January 2020: Masimo files its initial lawsuit against Apple, alleging patent infringement and theft of trade secrets.
• October 2020: Masimo files a complaint with the U.S. International Trade Commission (ITC), seeking an import ban on Apple Watch models containing the infringing technology. The ITC is a quasi-judicial federal agency that investigates unfair trade practices, including patent infringement, and has the power to issue exclusion orders.
• January 22, 2023: An ITC Administrative Law Judge issues an initial determination finding that Apple had infringed on certain Masimo patents related to pulse oximetry. This was a significant early victory for Masimo.
• October 26, 2023: The full ITC Commission affirms the ALJ’s finding, issuing a limited exclusion order prohibiting the import and sale of Apple Watch Series 9 and Apple Watch Ultra 2 models in the United States that incorporate the infringing blood oxygen technology.
• December 18, 2023: Faced with the impending ban and the conclusion of a 60-day presidential review period, Apple pre-emptively announces a halt to online sales of the Apple Watch Series 9 and Ultra 2 in the U.S. This temporary measure was followed by a halt in retail sales on December 24, underscoring the immediate and severe impact of the ITC ruling.
• December 26, 2023: The Biden administration, through the U.S. Trade Representative Katherine Tai, opts not to overturn the ITC’s exclusion order, allowing the ban to take effect. This decision was a critical blow to Apple, validating the ITC’s findings and Masimo’s claims.
• December 27, 2023: Apple appeals the ITC decision to the U.S. Court of Appeals for the Federal Circuit. Concurrently, an appeals court grants Apple a temporary stay on the import ban, allowing the company to resume sales of the Apple Watch Series 9 and Ultra 2.
• January 2024: Following the temporary stay, Apple resumes sales of the affected Apple Watch models in the U.S., but crucially, the blood oxygen feature is software-disabled on these devices. This workaround allowed Apple to continue selling its latest smartwatches while the legal process unfolded.
• August 2024 (Inferred from contextual clues): Apple introduces a redesigned version of its blood oxygen feature in the U.S., aiming to circumvent the patent infringement claims. This redesign fundamentally alters how the feature operates, moving significant processing power and the display of results from the Apple Watch itself to a paired iPhone.
• November 2024 (Inferred from contextual clues): The ITC initiates a new proceeding to scrutinize Apple’s redesigned blood oxygen feature, determining whether it still infringes on Masimo’s patents.
• This Week (Recent Developments):
  • Initial Determination on Redesign: ITC Administrative Law Judge Monica Bhattacharyya issues an initial determination, finding "no underlying act of direct infringement" by Apple’s redesigned blood oxygen feature on Masimo’s patents, even when paired with an iPhone.
  • Federal Circuit Affirms Original Ban: The U.S. Court of Appeals for the Federal Circuit affirms the original ITC exclusion order from 2023, meaning the original implementation of the blood oxygen feature remains banned.

The Redesigned Feature: A Strategic Pivot

Apple’s redesign of the blood oxygen feature was a calculated move to navigate the complex legal landscape. In essence, the new implementation shifts much of the data processing and the user interface from the watch to the iPhone. While a user still initiates a blood oxygen reading directly on their Apple Watch, the critical processing and the display of the results are now exclusively handled by the paired iPhone. This architectural change was intended to differentiate Apple’s current offering from the previously infringing version and, critically, to avoid direct infringement of Masimo’s patents, which primarily focused on the sensor and processing within the watch itself.

Judge Bhattacharyya’s initial determination that this redesigned version does not infringe Masimo’s patents is a significant, albeit preliminary, win for Apple. Her finding that there is "no underlying act of direct infringement" suggests that Apple’s technical workaround may be effective in avoiding the specific patent claims at issue. This determination, however, is not final. It must now be reviewed by the full ITC Commission for a conclusive ruling. Should the Commission uphold the ALJ’s finding, it would provide Apple with substantial legal clarity and allow it to continue offering the blood oxygen feature, albeit in its modified form, without further infringement concerns from this particular set of Masimo patents.

Confirmation of the Original Ban: A Lingering Shadow

While the news regarding the redesigned feature offers a potential path forward, the Federal Circuit’s affirmation of the original ITC exclusion order serves as a stark reminder of Apple’s initial legal misstep. This decision by the appellate court confirms that the original iteration of the blood oxygen monitoring technology, as implemented in the Apple Watch Series 9 and Ultra 2 before the software disablement, indeed infringed upon Masimo’s intellectual property.

The implication of this affirmation is straightforward: Apple cannot restore the original blood oxygen feature on its watches in the U.S. market. Any attempt to revert to the pre-redesign functionality would immediately place Apple in violation of the standing exclusion order, leading to renewed import bans and sales halts. This means that even if the redesigned feature is fully cleared by the ITC, Apple users in the U.S. will continue to experience the blood oxygen monitoring differently from users in other regions where the original feature remains active, or from how it was initially intended. The Federal Circuit’s ruling underscores the strength of Masimo’s original patent claims and the enforceability of ITC decisions.

Official Reactions and Future Avenues

Apple has predictably responded to these developments with a blend of satisfaction and defiance. In a statement to 9to5Mac, an Apple spokesperson expressed pleasure with Judge Bhattacharyya’s decision regarding the redesigned feature: "We thank the Administrative Law Judge for her careful consideration, and are pleased with the decision. For six years, Masimo has brought dozens of false claims against Apple, nearly all of which have been rejected. We will continue innovating to create industry-leading health, wellness, and life-saving features for our users." This statement highlights Apple’s long-standing contention that Masimo’s claims are largely unfounded and part of a broader harassment campaign.

Conversely, Apple voiced its disagreement with the Federal Circuit’s affirmation of the original ban. "We disagree with this decision and are evaluating all avenues for further review. We innovate every day to develop industry-leading health, wellness, and safety features, and will continue working to provide our users the best products and services in the world." This indicates that Apple may pursue further appeals, potentially seeking a rehearing en banc by the full Federal Circuit court or even appealing to the U.S. Supreme Court, though the latter is a rare and difficult path.

Masimo has not yet released a public statement on these specific, latest developments. However, given their consistent aggressive stance in protecting their intellectual property, it is reasonable to infer that they would view the Federal Circuit’s affirmation as a vindication of their initial claims and a confirmation of Apple’s original infringement. Their silence on the ALJ’s initial determination could suggest they are awaiting the full ITC Commission’s review, or preparing their own arguments against the ALJ’s findings.

Broader Implications for Health Tech and Intellectual Property

These rulings carry significant implications not just for Apple and Masimo, but for the broader health technology industry and the landscape of intellectual property law.

• For Apple’s Product Strategy: The validation of the redesigned feature, if upheld by the full ITC, provides Apple with a clear pathway to continue offering blood oxygen monitoring, albeit in a modified form. This is crucial for maintaining the Apple Watch’s competitive edge in the crowded wearable market, where health features are increasingly a differentiator. It also demonstrates Apple’s ability to adapt and innovate under legal pressure, finding workarounds that satisfy patent requirements.
• For Masimo’s Enforcement Strategy: While Masimo secured a significant victory with the permanent ban on the original feature, the potential clearance of Apple’s redesign presents a challenge. It highlights the difficulty of enforcing patents against competitors who can modify their products to avoid infringement. This may push Masimo to pursue new patent claims against the redesigned feature or to consider settlement discussions more seriously.
• Impact on Innovation and Competition: This case underscores the delicate balance between fostering innovation and protecting intellectual property. On one hand, strong patent protection incentivizes companies like Masimo to invest heavily in research and development. On the other, overly broad or aggressively enforced patents can stifle competition and force larger companies like Apple to expend resources on legal battles rather than pure innovation. The outcome of this case could influence how other tech giants approach integrating advanced health features, potentially encouraging more cautious licensing or robust in-house R&D.
• Consumer Experience: For consumers in the U.S., the situation remains somewhat fragmented. While they can access blood oxygen monitoring, the experience with the redesigned feature (requiring iPhone viewing) is different from the seamless on-watch display available in other markets or from the original intent. This could lead to some confusion or perceived degradation of functionality. However, the continued availability of the feature, even in a modified form, is preferable to a complete removal.
• Legal Precedent: The detailed scrutiny of Apple’s redesign by the ITC, and the Federal Circuit’s role in upholding ITC decisions, reinforces the power of these bodies in shaping market access for technologically advanced products. It sets a precedent for how "workaround" designs are evaluated in the context of existing patent infringement findings. The case also illustrates the multi-faceted nature of modern patent disputes, often involving simultaneous proceedings in different legal forums.

The Path Forward

The saga is far from over. The initial determination by Judge Bhattacharyya regarding the redesigned feature now proceeds to the full ITC Commission for a final determination. This review process can take several months, during which both Apple and Masimo will have opportunities to present their arguments. Simultaneously, Apple’s statement about "evaluating all avenues for further review" regarding the Federal Circuit’s affirmation of the original ban suggests potential for continued litigation at higher appellate levels, which could extend the legal battle for years.

Ultimately, this ongoing dispute highlights the intense competition and significant intellectual property stakes within the rapidly expanding health technology sector. As devices like the Apple Watch become increasingly sophisticated and integrated into personal health management, the legal battles over the underlying technologies are likely to become more frequent and complex, shaping the future of innovation in consumer health wearables.